Since commencing operations in 2008, viDA has been dedicated to the pursuit of first-in-class therapeutics with the potential to address critical medical problems. Building on our expertise on the serine protease family, Granzymes, viDA is expanding its research and development efforts in the field of Granzyme biology under the guiding principle of addressing therapeutic areas with significant unmet medical need, and a validated development path to approval.
A major therapeutic platform at viDA is focused towards inhibiting the activity of Granzyme B (GzmB). Specifically, viDA is developing inhibitors targeting extracellular GzmB to treat a variety of autoimmune and chronic inflammatory diseases including a number of orphan indications.
viDA is a pioneer in research to understand the biology of granzymes, a granule secreted enzyme that in the extracellular environment targets and degrades key proteins that make up the extracellular matrix. Research implicates Granzymes in multiple pathogenic processes. Read More.
viDA continues to expand our library of proprietary inhibitors (small molecule and biological) targeting extracellular GzmB for different routes of administration to treat a variety of diseases in which GzmB-mediated pathologies play a key role. Read More.
Fibrosis, a pathological process of excessive fibroblast proliferation and aberrant collagen production, plays a major role in diseases affecting millions of patients and smaller patient populations. GzmB is a common denominator in in many forms of fibrosis and mechanistic studies have shown that GzmB cleaves key proteins that are necessary for regulating fibroblast proliferation and normal collagen production and assembly. viDA believes GzmB inhibition therapy may be applicable to a number of fibrotic indications. READ MORE
• Idiopathic Pulmonary Fibrosis
• Cardiac Fibrosis
Autoimmune diseases are a complex and diverse group of disorders characterized by an aberrant immune response in which immune cells recognize self tissues as foreign tissues resulting in the attack and injury of host cells and tissues. There are over 80 types of autoimmune diseases characterized to date and the NIH estimates nearly 23.5 million Americans live with an autoimmune condition. viDA believes GzmB inhibition therapy may be applicable to a number of autoimmune indications. READ MORE
• Progressive Multiple Sclerosis
• Kawasaki Disease
• Autoimmune Bullous Disorders
• Alopecia areata
Chronic systemic inflammation is an underlying cause of many seemingly unrelated, age-related diseases. As humans grow older, systemic inflammation can inflict devastating degenerative effects throughout the body. viDA is pursuing GzmB therapy for a number of these chronic inflammatory indications. READ MORE
• Aneurysm (Abdominal, Thoracic, Cerebral)
• Advanced Atherosclerosis
• Chronic Obstructive Pulmonary Disease
Chronic Inflammatory Disease
Our initial aim is to show the clinical potential of inhibiting extracellular GzmB first in the area of dermatology, before attempting clinical development in other indications. Dermatology offers potential economic and timeline advantages in moving our lead program into a clinical pathway for drug development and also provides opportunities to explore several dermatological orphan indications. READ MORE
• Skin burns
• Cutaneous Leishmaniasis
• Photoaging (Skin Aging)